Correlation of days of illness on which oseltamivir was started with outcome in swine flu patients, in Government Medical College, Aurangabad (Jan-2015 to May 2015)
Keywords:Oseltamivir, Survival in swine flu, Oseltamivir given within 48 hours
Background: Since 2009, Government Medical College, Aurangabad, a tertiary care hospital in the Marathwada region of Maharashtra, India, has been regularly admitting cases of pneumonia and ARDS, that are labeled as swine flu suspects. Oseltamivir is effective in swine flu cases if given within 48 hours and better, within 24 hours of start of illness. However most of our patients do not get oseltamivir within 48 hours. Hence we decided to compare the outcome in patients who received oseltamivir within 48 hours and after that.
Methods: This is an observational, cross-sectional study comparing the time lag between the start of symptoms and getting the first dose of oseltamivir. 59 H1N1 positive patients were admitted to the swine flu ward between January to May 2015. We compared the two groups, one that received oseltamivir within 48 hours of start of symptoms and one that received after 48 hours and compared it with the outcome, i. e survival or death.
Results: 38 patients (64.40%) in our study belonged to the age group of 31-50. Out of 59 positive patients, only 7 received oseltamivir within 48 hours, of whom 4 died. 52 received oseltamivir after 48 hours of whom 20 died. All the 11 who were given non-invasive ventilation, whereas only 1 of the 25 on invasive ventilation survived.
Conclusions: Oseltamavir does not appear to have made a difference for survival whether it was given within 48 hours as compared to after 48 hours of onset of symptoms. However, these two groups were not comparable.
Ministry of Health and Family Welfare Files. Guidelines on risk categorization, 2015. Available at: http://mohfw.gov.in/showfile.php?lid=3071.
FDA. Tamiflu background information and utilization patterns, 2015. Available at: Http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/PediatricAdvisoryCommittee/UCM303004.pdf.
Moscona, Schirmer, Holodniy. Oseltamivir for treatment and prophylaxis of influenza infection, Expert Opin Drug Saf. 2009 May;8(3):357-71.
Richard Starlin. Influenza virus. In: Richard Starlin, Michele Cabellon, Rebecca Chandler, Erik Dubberke, Melissa Norton, Erin Quirk, eds. The Washington Manual - Infectious Diseases Subspecialty Consult. 2nd ed. Philadelphia: Lippincott Williams & Wilkins; 2005: 306.
Laurence Brunton, Keith Parkar, Donald Blumenthal, Lain Buxton. Influenza - H1N1. In: Laurence Brunton, Keith Parkar, Donald Blumenthal, Lain Buxton, eds. Goodman and Gilman’s Pharmacological Basis of Therapeutics. 12th ed. New York, NY: McGraw Hill Education; 2011: 839.
Hugh J. Field, Alan P. Johnson. Oseltamivir (Tamiflu) and its use against seasonal, avian and pandemic strains of influenza. J Antimicrob Chemother. 2010 Apr;65(Suppl 2):11-24.
Derlet RW, Sandrock CE, Nguyen HH, Lawrence R. Influenza, 2010. Available at: http:// emedicine.medscape.com/article/219557-overview. Accessed 14 October 2010.
Novel Swine-Origin Influenza A (H1N1) Virus Investigation Team, Dawood FS, Jain S, Finelli L, Shaw MW, Lindstrom S, et al. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med. 2009 Jun;360(25):2605-15.
Harper SA, Bradley JS, Englund JA, File TM, Gravenstein S, Hayden FG, et al. Seasonal influenza in adults and children - diagnosis, treatment, chemoprophylaxis, and institutional outbreak management: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis. 2009;48(8):1003-32.
CDC. Influenza antiviral medications: summary for clinicians, 2015. Available at: http://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm.
Nicholas A. Boon, Nicki R. Colledge, Brian R. Walker. Oseltamivir. In: Nicholas A. Boon, Nicki R. Colledge, Brian R. Walker, eds. Davidson: Principal and Practice of Medicine. 20th ed. London: Churchill Livingstone; 2006: 157.
Fred Y. Aoki, Karen E. Doucette. Oseltamavir: a clinical and pharmacological perspective. 2001, Oct;2(10):1671-83.
Sherwood L. Gorbach, John G. Bartlett, Neil R. Blacklow. Oseltamivir. In: Sherwood L. Gorbach, John G. Bartlett, Neil R. Blacklow, eds. Infectious Diseases. 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 2004: 309
Maryanne Hochadel. The AARP guide to pills: essential information. In: Maryanne Hochadel, eds. A Guide. New York: Sterling Pub Co Inc; 2006.
CDC. Prevention and control of influenza: recommendations of the Advisory Committee on immunisation Practice (ACIP). MMWR. 1999;48(No. RR-4):1-28.
Jefferson T, Jones M, Doshi P, Del Mar C, Dooley L, Foxlee R. Neuraminidase inhibitors for preventing and treating influenza in healthy adults: systematic review and meta-analysis. BMJ. 2009;339:B51O6.
Kasper, Fauci, Kauser, Longo, Jameson, Loscalzo. Antiviral compounds. In: Kasper, Fauci, Kauser, Longo, Jameson, Loscalzo, eds. Harrison’s Principles of Internal Medicine. New York: McGraw-Hill; 15th ed. 2001: 1213-1214.
Levitt JE, Matthay MA. Clinical review: early treatment of acute lung injury--paradigm shift toward prevention and treatment prior to respiratory failure. Crit Care. 2012 Jun;16(3):223.